Two advisory committees appointed by the US Food and Drug Administration (FDA) have voted in favor of ALKS 3831, a combination of olanzapine and the novel molecular entity samidorphan, Alkermes announced.
Patients initiated on long-acting injectables for the treatment of schizophrenia had fewer hospitalizations and emergency department visits, compared with patients treated with oral antipsychotics, according to a poster presented at Psych Congress…
The metabolic profile of lumateperone 42 mg appears favorable, according to a post hoc analysis of a trio of studies involving patients with schizophrenia. Researchers shared their findings at Psych Congress 2020.
In patients with recent-onset schizophrenia, the rate of major treatment failure with longer treatment was lower with paliperidone palmitate than with oral antipsychotics, according to a poster presented at Psych Congress 2020.
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
A large-scale analysis of insurance databases found a high prevalence of medical and psychiatric comorbidities among patients with schizophrenia, compared with matched controls, according to a poster presented at Psych Congress 2020.
HP-3070, the asenapine transdermal system, has a more predictable absorption profile and lower peak-to-trough fluctuations than sublingual asenapine, according to a poster presented at Psych Congress 2020.